Elan/Wyeth Alzheimer’s Treatment moves into Phase III trials
from http://biz.yahoo.com/ap/070521/wyethelanmover.html?.v=1
AP
Wyeth, Elan Shares Jump on Study Plans
Monday May 21, 10:41 am ETWyeth and Elan Shares Rise on Plans for Late-Stage Study on Alzheimer’s Treatment Candidate
NEW YORK (AP) — Shares of drug developers Wyeth and Elan Corp. jumped Monday after the companies said they plan on asking for approval to move their Alzheimer’s treatment candidate bapineuzumab into late-stage studies.…The companies were waiting for Food and Drug Administration approval to move the drug candidate into Phase III clinical trials, with expectations for a start date in the second half of 2007, months ahead of the previous outlook. Results from the mid-stage, or Phase II, clinical trials aren’t expected until 2008.
….
Unlike current drugs that treat the symptoms, the new class is aimed at stopping the development of amyloid plaques in the brain and treating what is believed to be the cause of the condition.
ED. - Great news as it looks like the Phase II results are promising. One step closer to another treatment for AD.
